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Computational models of reinforcement learning have helped dissect discrete components of reward-related function and charac-
terize neurocognitive deficits in psychiatric illnesses. Stimulus novelty biases decision-making, even when unrelated to choice
outcome, acting as if possessing intrinsic reward value to guide decisions toward uncertain options. Heightened novelty seeking
is characteristic of attention deficit hyperactivity disorder, yet how this influences reward-related decision-making is computation-
ally encoded, or is altered by stimulant medication, is currently uncertain. Here we used an established reinforcement-learning task
to model effects of novelty on reward-related behaviour during functional MRI in 30 adults with attention deficit hyperactivity
disorder and 30 age-, sex- and IQ-matched control subjects. Each participant was tested on two separate occasions, once ON and
once OFF stimulant medication. OFF medication, patients with attention deficit hyperactivity disorder showed significantly im-
paired task performance (P = 0.027), and greater selection of novel options (P = 0.004). Moreover, persistence in selecting novel
options predicted impaired task performance (P = 0.025). These behavioural deficits were accompanied by a significantly lower
learning rate (P = 0.011) and heightened novelty signalling within the substantia nigra/ventral tegmental area (family-wise error
corrected P5 0.05). Compared to effects in controls, stimulant medication improved attention deficit hyperactivity disorder par-
ticipants’ overall task performance (P = 0.011), increased reward-learning rates (P = 0.046) and enhanced their ability to differen-
tiate optimal from non-optimal novel choices (P = 0.032). It also reduced substantia nigra/ventral tegmental area responses to
novelty. Preliminary cross-sectional evidence additionally suggested an association between long-term stimulant treatment and a
reduction in the rewarding value of novelty. These data suggest that aberrant substantia nigra/ventral tegmental area novelty
processing plays an important role in the suboptimal reward-related decision-making characteristic of attention deficit hyperactivity
disorder. Compared to effects in controls, abnormalities in novelty processing and reward-related learning were improved by
stimulant medication, suggesting that they may be disorder-specific targets for the pharmacological management of attention deficit
hyperactivity disorder symptoms.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is an early-
onset neurodevelopmental disorder characterized by symp-
toms of inattention, impulsivity and/or hyperactivity with
symptoms persisting into adulthood in up to 50% of pa-
tients (Simon et al., 2009). Within the brain, both inatten-
tive (Volkow et al., 2007) and hyperactive/impulsive (Rosa
Neto et al., 2002) symptoms are linked to abnormalities in
dopaminergic function, particularly within the mesolimbic
reward system. Correspondingly, impaired reward learning
(Frank et al., 2007; Thoma et al., 2015) has been theorized
to play a central role in both the symptomatic expression
and aetiology of this disorder (Luman et al., 2010). Several
theoretical approaches have emerged to describe how
abnormalities in reward function are linked to the symp-
tomatology of ADHD (Luman et al., 2010). However, a
framework that can explain these reward abnormalities
across both neurobiological and neurocomputational
levels remains to be articulated.
Over the past decade temporal difference and related
Rescorla-Wagner learning models that allow computation
of ‘hidden’ learning signals and quantification of learning
from reward in vivo have provided a powerful method for
characterizing human reward-related behaviour (Steinberg
et al., 2013). Through calculation of trial-by-trial predic-
tion error signals these models have demonstrated a tight
coupling between reward-related learning signals and dopa-
minergic neuronal activity (Schultz et al., 1997; Hollerman
and Schultz, 1998) within the substantia nigra/ventral teg-
mental area and ventral striatum (Montague et al., 1996;
Waelti et al., 2001; McClure et al., 2003; O’Doherty et al.,
2003; Bayer and Glimcher, 2005). This approach has
helped clarify mechanisms of impaired reward-related pro-
cessing in other disorders characterized by dopaminergic
dysfunction including schizophrenia and Parkinson’s dis-
ease (Murray et al., 2008; Rutledge et al., 2009). More
broadly, these models also present a theoretical framework
for characterizing the behavioural impact of other salient
influences, such as stimulus novelty, on decision-making
processes and their instantiation within the brain
(Wittmann et al., 2008). Importantly, however, there is as
yet no precise account of how reinforcement learning to
reward is altered in ADHD, or how it is ameliorated by
stimulant medication (Frank et al., 2007; Luman et al.,
2010; Thoma et al., 2015).
Preliminary work using computational modelling to
simulate learning of reward, has indicated several candidate
mechanisms that could account for ADHD-associated im-
pulsivity (Williams and Dayan, 2005). For instance,
reduced learning rates (slower updating of reward values
with experience) are associated with reduced dopamine
levels (Rutledge et al., 2009), and may therefore mediate
the association between impulsive reward-seeking and
hypodopaminergia in ADHD (Williams and Dayan,
2005). Such an account may also help explain the efficacy
of stimulant medication in improving reward-learning
(Frank et al., 2007; Thoma et al., 2015), since dopamin-
ergic medications enhance reward-related learning rates in
Parkinson’s disease (Rutledge et al., 2009).
In ADHD, aberrant novelty processing is a related, but
critically underexplored, component of reward dysfunction.
Stimulus novelty is a potent trigger for activation of dopa-
minergic neurons within the substantia nigra (Schultz,
1998); a mechanism that can bias preference towards
novel options and drive exploratory behaviour (Kakade
and Dayan, 2002; Wittmann et al., 2008). Novelty prefer-
ence is highly adaptive, enabling identification of new
sources of potential reward and reducing uncertainty asso-
ciated with unfamiliar stimuli. However, novelty preference
also entails risk. Aberrantly high novelty valuation is linked
to significant personal harm, including development of sub-
stance abuse (Wills et al., 1994). It is therefore noteworthy
that heightened novelty-seeking is robustly observed in
ADHD (Downey et al., 1997; Lynn et al., 2005; Jacob
et al., 2014). Furthermore, novelty-seeking personality
traits (Ebstein et al., 1996; Ekelund et al., 1999; Strobel
et al., 1999; Tomitaka et al., 1999; Okuyama et al., 2000;
Kluger et al., 2002; Munafo et al., 2008; Roussos et al.,
2009) and ADHD (LaHoste et al., 1996; Rowe et al., 1998;
Smalley et al., 1998; Faraone et al., 1999, 2001; Barr et al.,
2000; Eisenberg et al., 2000) share genetic correlates in
dopamine receptor (particularly DRD4) polymorphisms.
To date, no work has specifically examined how increased
novelty-seeking impacts reward learning in ADHD.
Reinforcement learning models may again help address
this. Computational accounts of reward learning propose
that novelty encourages exploratory behaviour through a
fictive ‘bonus’ signal that enhances the reward value of
novel stimuli (Kakade and Dayan, 2002). Supporting this,
both novelty bonus and reward prediction error signals are
associated with phasic dopaminergic activity in mesolimbic
reward pathways (Steinfels et al., 1983; Ljungberg et al.,
1992; Horvitz et al., 1997; Kakade and Dayan, 2002;
Bunzeck and Duzel, 2006; Wittmann et al., 2008; Zald
et al., 2008; Schiemann et al., 2012). Correspondingly,
increased novelty bonus signals are observed in patients
with impulse control disorders associated with
Parkinson’s disease (Djamshidian et al., 2011). We hy-
pothesize that similar changes underpin impairments in im-
pulse control characteristic of ADHD. Furthermore, it
remains unclear why stimulant medications (that enhance
synaptic dopamine) improve hyperactive/impulsive symp-
toms in ADHD, given the expectation that they would
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heighten novelty ‘bonus’ signals and potentially exacerbate
these symptoms.
To address this, we tested 30 patients with ADHD and
30 matched control subjects on a reinforcement-learning
task shown to be sensitive to effects of stimulus novelty
on reward-related behaviour. Each participant completed
the task during functional MRI on two separate occasions,
once after taking stimulant medication and the other after
placebo.
Materials and methods
Participants
Thirty adult ADHD patients were recruited from specialist
clinics at Sussex Partnership NHS Foundation Trust.
Assessment included semi-structured interview using the
Diagnostic Interview for ADHD in Adults (DIVA), completion
of the Conners’ ADHD self-report long version and Wender
Utah questionnaires, informant history and wherever possible
review of school reports. All had DSM-IV confirmed diagnoses
of ADHD. Control participants were recruited through classi-
fied advertisements and university mailing lists. Participants
gave written informed consent following full explanation of
the experimental procedures. Local and national ethical ap-
provals were obtained from Brighton and Sussex Medical
School (14/014/HAR; 12/131/HAR) and the East of England
(Hertfordshire) National Research Ethics Committee (refer-
ence: 12/EE/0256).
Exclusion criteria included past or current history of any
neurological or psychiatric history, other than anxiety and/or
unipolar depressive disorder currently in remission, past his-
tory of significant head injury, and current drug or alcohol
abuse. Controls were additionally excluded if they had a his-
tory of serious cardiovascular conditions including cardiomy-
opathy, coronary artery disease, heart failure, ventricular
arrhythmia or hypertension, current or recent use of mono-
amine oxidase inhibitors, coumarin anticoagulants, anticonvul-
sants or antipsychotics or a diagnosis of glaucoma. Of note,
ADHD participants were routinely screened for these potential
contra-indications to stimulant medication at clinical
assessment.
ADHD and control participant were matched on age
[mean  standard deviation (SD) ADHD: 33.7  9.51 years,
controls: 32.6  9.54 years, F(1,58) = 0.20, P = 0.66], IQ
[ADHD: 109.0  6.57, controls: 110.1  7.06, F(1,58) = 0.40,
P = 0.53], gender and handedness (Table 1). ADHD partici-
pants scored highly on both inattentive and hyperactive/impul-
sive domains. Each patient was managed on a stable regimen of
methylphenidate (minimum 18mg) or dexamphetamine (min-
imum 10mg) for at least 2 months prior to study enrolment.
Experimental design
We used a randomized, repeated-measures, double-blind, pla-
cebo-controlled study design in which all participants attended
two experimental sessions separated by a minimum of 1 week.
Patients with ADHD were required to abstain from their regu-
lar ADHD medication for the test day and 2 days prior to
testing. A.S., who performed all participant testing and pro-
cessing of all behavioural and imaging data, was blind to treat-
ment allocation. N.A.H. (a qualified doctor) was aware of
treatment allocation for safety reasons but took no part in
participant testing or data processing. At the start of the first
session, all participants were randomized to receive either
stimulant medication or placebo using sealed coded envelopes.
The alternate treatment was given on the second experimental
session. ADHD participants were administered either their
Table 1 Participant demographics and ADHD scores
Measure Mean (SD) F P
ADHD Controls
n 30 30 – –
Male 19 19 – –
Female 11 11 – –
Age 33.7 (9.51) 32.6 (9.54) 0.2 0.66
Handedness – –
Right-dominant 28 29 – –
Left-dominant 1 1 – –
Ambidextrous 1 0 – –
FSIQa 109.0 (6.57) 110.1 (7.06) 0.4 0.53
CAARS ADHD Index 24.0 (5.30) 8.6 (5.01) 133.21 50.001
Attention/memory problems 26.7 (5.46) 9.9 (5.67) 123.48 50.001
Hyperactivity/motor restlessness 24.4 (6.46) 11.3 (5.68) 68.81 50.001
Impulsivity/emotional lability 23.7 (7.36) 7.6 (4.12) 109.13 50.001
Problems with self-concept 11.2 (4.72) 5.6 (4.45) 22.5 50.001
DSM total ADHD score 37.6 (9.03) 12.8 (6.92) 159.66 50.001
DSM Inattention 19.3 (4.46) 7.0 (4.55) 125.28 50.001
DSM Hyperactivity and Impulsivity 18.3 (5.66) 5.7 (3.83) 110.44 50.001
CAARS = Conners’ Adult ADHD Rating Scale; DSM = Diagnostic and Statistical Manual of Mental Disorders; FSIQ = Full scale intelligence quotient.
aAs estimated by National Adult Reading Test (NART) scores.
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normal morning dose of stimulant medication or an inactive
placebo. Control participants received either 20mg of methyl-
phenidate or placebo.
Reinforcement-learning task with
novelty manipulation
After drug administration, participants were immediately
familiarized with 32 greyscale landscape images (Bunzeck
and Duzel, 2006) over a 15-min session. This timing was im-
portant to ensure equivalent encoding (familiarization) across
drug and placebo conditions. Ninety minutes after drug
dosing, participants completed an MRI session (75-min dur-
ation), including three runs of the reinforcement-learning task
(three-armed bandit task) encompassing a novelty manipula-
tion (Wittmann et al., 2008; Djamshidian et al., 2011) (Fig. 1).
Task structure followed Wittmann et al. (2008) to aid com-
parison with previously published findings. Task performance
was timed to coincide with peak drug dopamine transporter
occupancy (Volkow et al., 1998).
Computational modelling of choice
behaviour
We characterized each participant’s trial-to-trial choices using
the same model as Wittmann et al. (2008). This model
included four free parameters:  learning rate,  inverse
temperature or choice randomness, and Qf and Qn, the initial
values of familiar and novel stimuli, respectively. Initial values
of each picture were set to Qf if the picture had been pre-
exposed during the familiarization phase, and Qn if not.
Values for the chosen option (Q) were updated according to
the delta () rule:
Q c; t þ 1ð Þ ¼ Q c; tð Þ þ  • ðtÞ ð1Þ
Where  denotes the reward (r) prediction error:
 tð Þ ¼ r tð Þ Qðc; tÞ ð2Þ
The probability of choosing an option was modelled accord-
ing to a softmax selection strategy, where the probability of
choosing an option c (out of the three options k) on trial t is:
Pðc; tÞ ¼ expð • Qðc; tÞÞX3
k¼1expð • Q k; tð ÞÞ
ð3Þ
Model parameters were optimized on a per subject, per ses-
sion basis using the interior point algorithm implemented in
MATLAB’s fmincon function to minimize the negative log-
likelihood of the observed sequence of choices. Model fit did
not differ between ADHD and control groups. Novelty bonus
was calculated as QnQf, with a positive value reflecting a
preference for novel over familiar options.
Figure 1 Novelty processing task. (A) Image sets: A set of 64 greyscale pictures (SET A or SET B) was randomly allocated for each session.
(B) Pre-familiarization: participants were familiarized to half of the image set by passive, then active viewing. (C) Three-armed bandit task: during
functional MRI, participants chose between three options (images) on each trial. Each option had a fixed probability (mean: 33%) of winning £1.
Participants were instructed to choose options that maximized their total reward. Each trial consisted of stimulus presentation (3.5 s), choice
feedback (3 s), and reward feedback (superimposed £1 or £0) (1.5 s). If participants failed to respond, ‘No response’ was displayed (4.5 s). There
was a jittered intertrial interval (1.5–3 s). Option locations were randomly shuffled between trials. (D) On 25% of trials one option was randomly
replaced by a new one from the image set. Images differed in reward value, but novel and familiar (pre-familiarized) images had the same reward
probability distributions (mean 33%). The task was split into three 13-min runs, each containing 80 consecutive trials.
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To study effects of pharmacological manipulation and
ADHD diagnosis on novelty processing we followed
Wittmann’s approach and fit a second model where the initial
value of novel and familiar stimuli were set equal i.e. Qn =Qf
then compared the two models on the entire dataset (pooled
over all subjects) using a likelihood ratio test. This model
generated a second sequence of values Qbase(c,t) and prediction
errors base(t), representing baseline values without the add-
itional effect of novelty. By comparing the two models, we
calculated the additive value Qadd(c,t) = (Q(c,t)Qbase(c,t))
and prediction error add(t) = (c,t)  base(t) associated with
stimulus-novelty. Behavioural outcome measures included the
four free model parameters, a, b, Qn and Qf. To study novelty
specifically, we examined novelty bonus (QnQf), tendency to
pick novel options on their first presentation, and number of
consecutive trials in which the novel object was selected.
Model-based regressors were generated for analysis of the
neuroimaging data by entering each participant’s actual se-
quence of rewards and choices within the learning model to
produce per-subject, per-trial estimates of the values Q(c,t) and
error signals (t).
MRI
T2*-weighted echo planar images were acquired on a 1.5T
Siemens Avanto equipped with a 32-channel head-coil using a
30 tilted acquisition to reduce orbitofrontal dropout
(Deichmann et al., 2003). Each volume provided whole brain
coverage (34 interleaved ascending 3mm axial slices, 1mm
interslice gap, echo time 43ms: repetition time 2.52 s, in-plane
resolution 3mm). Multi-parameter mapping using three co-loca-
lized 3D multi-echo flash sequences was additionally acquired to
provide magnetization transfer images with high contrast for
our subcortical regions of interest (1.25mm3 resolution,
proton density: repetition time = 24ms, echo time = 2.51–
21.9ms, flip angle = 6; T1: repetition time = 19ms, echo
time = 2.51–10.82ms, flip angle = 20; magnetization transfer:
repetition time = 30ms, echo time = 2.51–10.82ms, flip
angle = 12) (Helms et al., 2009; Sethi et al., 2017).
Magnetization transfer images were segmented then normalized
in SPM8 (http://www.fil.ion.ucl.ac.uk/spm/) to aid group level
anatomical localization. Diffusion weighted MRI and multi-
echo resting state datasets were also acquired, though are not
reported here.
Functional MRI data were analysed in an event-related
manner in SPM8. Preprocessing consisted of spatial realign-
ment, segmentation and normalization to a standard echo-
planar imaging template then spatial smoothing with an
8mm full-width at half maximum Gaussian kernel.
Modelling of the data exactly replicated the approach used
by Wittmann et al. (2008): each trial was modelled with im-
pulse regressors at two time points: time of picture presenta-
tion (taken to be the time of decision), and time of outcome
presentation (3 s after key press), base(t) and add(t) and
Q-values (Qbase(c,t) and Qadd(c,t)), were used as parametric
modulators of outcome and cue onsets, respectively. All regres-
sors were convolved with a canonical haemodynamic response
function and its temporal derivative. The six movement par-
ameters were included as additional regressors to account for
residual effects of scan-to-scan motion.
To enable inference at the group level, the coefficient esti-
mates for the model-based regressor (base(t)) and the novelty
bonus signal (Qadd(c,t) and add(t)) from each individual sub-
ject and session were taken to allow second-level, random-ef-
fects group statistics to be computed in a mixed measures
ANOVA [repeated factor: (drug, placebo), between-subject
factor: group (ADHD, control)].
A priori regions of interest
Bilateral ventral striatum and substantia nigra/ventral tegmen-
tal area were defined as a priori regions of interest, based on
Wittmann et al.’s published findings. The ventral striatum
region of interest was defined using the Martinez mask,
which includes the nucleus accumbens and ventral caudate
and putamen rostral to the anterior commissure (bilateral
volume 5256mm3) (Martinez et al., 2003). Magnetization
transfer images allow the substantia nigra to be easily distin-
guished from surrounding structures (Helms et al., 2009; Sethi
et al., 2017). The substantia nigra/ventral tegmental area
region of interest was therefore produced by manual tracing
on the group mean magnetization transfer template produced
using all participants’ normalized magnetization transfer satur-
ation maps (bilateral volume 1792mm3). Results are reported
for clusters surviving a cluster forming threshold of P50.001
and a stringent family-wise error (FWE) extent threshold of
P5 0.05 for the whole brain or appropriate region of interest.
Questionnaires
The Conners self-report Adult ADHD Rating Scale (CAARS;
Conners et al., 1999) was used to index current ADHD symp-
tom severity and the Tridimensional Personality Questionnaire
(TPQ; Cloninger et al., 1991) to measure trait novelty-seeking.
The Beck Depression Inventory (BDI; Beck et al., 1996) and
State and Trait Anxiety Inventory (STAI; Spielberger, 1983)
were used to assess depression and anxiety scores, respectively.
The Multidimensional Personality Questionnaire (Tellegen and
Waller, 2008) was also administered for use in a separate
study. Behavioural analyses were performed in SPSS using
mixed-measures ANOVAs followed by post hoc t-tests. Non-
parametric Spearman’s rho was used to assess relationships
between behavioural measures to account for non-normal dis-
tributions within the data.
Behavioural analyses
Planned analyses assessed whether the model parameters a, 
and total amount won on the task were affected by group or
medication status using separate mixed-measures ANOVAs
with group (between-subject) and medication (within-subject)
factors. Planned analyses of effects of group and medication
on novelty were assessed through inclusion of an additional
within-subject novelty factor (Qn, Qf). To assess for long-term
effects of medication on the behavioural novelty bonus, we
also performed planned Spearman’s rho correlations between
the novelty bonus and length of time on medication in months.
Results of the above analyses were then further investigated
using several post hoc behavioural tests as detailed in the rele-
vant results sections.
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Results
Sample characteristics
Mean (SD) equivalent daily dose of methylphenidate was
50.0  21.0mg and mean psycho-stimulant treatment time
32.7 (39.6) months for the ADHD group (see
Supplementary material for further details). As anticipated,
the ADHD group scored significantly higher on all CAARS
subscales (Table 1). ADHD participants had significantly
higher scores for depression and trait anxiety [BDI:
ADHD = 13.7 (8.6), controls = 5.6 (6.6), F(1,58) =
17.01, P5 0.001. STAI trait: ADHD = 53.5  11.0, con-
trol s = 36.5  10.7, F(1,58) = 36.51, P5 0.001], though
group differences in antidepressant use were not significant
(ADHD = 6, controls = 1, Fischer’s exact test; P = 0.10).
BDI and STAI scores did not significantly correlate with
variables of interest (task performance, novelty bonus, a,
; all P4 0.05).
Consistent with larger population studies (Downey et al.,
1997; Lynn et al., 2005; Jacob et al., 2014), ADHD partici-
pants scored significantly higher on novelty-seeking and
harm-avoidance factors of the TPQ [novelty-seeking:
ADHD = 22.9  4.8, controls = 17.6  5.6, F(1,57) = 15.29,
P5 0.001; harm-avoidance: ADHD = 17.1  7.5, con-
trols = 11.9  7.5, F(1,57) = 15.29, P = 0.01], but not
reward-dependence [ADHD = 13.0  4.0, controls = 12.3
 3.8, F(1,57) = 0.55, P = 0.46] or persistence [ADHD
= 5.3  2.3, controls = 4.6  2.0, F(1,56) = 1.38, P = 0.245].
Behavioural responses
OFF medication, ADHD patients showed impaired perform-
ance on the reinforcement-learning task (task performance)
compared to controls {amount won [mean  standard error
(SE)]: ADHD: £86.3  1.76, controls: £91.8  1.80,
F(1,58) = 5.17, P = 0.027}. Moreover, stimulant medication
had significantly different effects across the two groups
(Group  Drug interaction), significantly enhancing ADHD
participants’ performance compared to effects on controls
who showed an inverse pattern of effects [change in amount
won (mean  SE): ADHD: £4.2  2.26, controls:
£4.2  2.22; F(1,58) = 6.95, P = 0.011]. Post hoc t-test
confirmed a trend towards increased performance following
stimulant medication in the ADHD participants
[t(29) = 1.84, P = 0.077] and a converse trend towards
decreased performance in controls [t(29) = 1.89,
P = 0.068].
To investigate these behavioural differences in more
detail we then examined individual model parameters.
Following Wittmann, we first tested whether the novelty
bonus model better accounted for participants’ choices
than the simpler model that initialized both sets of pictures
with the best shared initial value (Qn =Qf), and found that
it did (likelihood ratio test, 1 degree of freedom P5 0.001).
Consistent with what we observed for task performance,
unmedicated patients with ADHD showed a significantly
lower learning rate than unmedicated controls
[t(58) = 2.34, P = 0.011]. Stimulant medication also
demonstrated dissociable effects on learning rates across
groups [Group  Drug interaction F(1,58) = 4.17,
P = 0.046] significantly increasing learning rates in ADHD
(mean  SE, stimulant: 0.48  0.06; placebo: 0.39  0.04)
compared to effects on controls (stimulant: 0.46  0.06;
placebo: 0.54  0.05). However, though differences in ef-
fects of stimulant medication could be observed between
groups, these did not survive within group comparisons
(post hoc t-test P40.1). Choice-randomness (b) did not
significantly differ between groups or across medication
condition (all P40.1) (Table 2).
Across groups, unmedicated participants showed a strong
preference for novel compared to familiar stimuli: [i.e.
Qn4Qf; novelty bonus = £0.039  0.01; F(1,58) = 10.84,
P5 0.005; see Table 2 for Qf and Qn for each condition
and group separately]. Indeed, unmedicated ADHD partici-
pants expressed a novelty bonus more than double that
observed in controls (£0.054  0.018 versus
£0.024  0.015), though due to high interindividual vari-
ability this effect did not reach statistical significance
[F(1,58) = 1.59, P = 0.213].
To investigate whether group differences in novelty pref-
erence were expressed at the behavioural level, we then
examined how frequently individuals selected novel com-
pared to familiar stimuli on their first appearance.
Unmedicated ADHD participants were significantly more
likely than controls to choose novel compared to familiar
options on their first presentation [Group  Familiarity:
F(1,58) = 8.83, P = 0.030] with post hoc analysis indicating
a heightened salience of intrinsically ‘novel’ stimuli rather
than an increased propensity to choose all newly intro-
duced stimuli [% novel items selected: ADHD:
16.8  1.23; control: 12.3  1.09, F(1,58) = 8.83,
P = 0.004; % familiar items selected: ADHD: 15.3  1.03;
control: 14.0  1.05; F(1,58) = 0.72, P = 0.399].
Table 2 Model parameter estimates in ADHD and
controls
Measure Mean scores (SE)
ADHD Controls
Placebo
Qn 0.57 (0.07) 0.46 (0.05)
Qf 0.52 (0.06) 0.45 (0.06)
a 0.39 (0.04) 0.54 (0.05)
b 7.58 (2.06) 8.69 (2.29)
Drug
Qn 0.62 (0.06) 0.53 (0.05)
Qf 0.56 (0.06) 0.49 (0.05)
a 0.48 (0.06) 0.46 (0.06)
b 7.18 (1.54) 7.58 (1.27)
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Relating novelty responses to drug-
induced changes in task performance
We next investigated the relationship between novelty and
task performance, by testing whether differences in ADHD
participants’ responses to novel versus familiar stimuli
underpinned interindividual differences in drug-related en-
hancement of performance on the task [(money won on
stimulantmoney won on placebo) / money won on pla-
cebo]. As anticipated, better performance ON medication
was associated with a lower (i.e. more accurate) initial
valuation of both novel (Qn) and familiar (Qf) stimuli
(both rho = 0.53, P = 0.009). However, persistence in se-
lecting novel and familiar stimuli after their initial intro-
duction differentially predicted task performance.
Specifically, when ADHD participants were unmedicated,
poorer performance was associated with greater persist-
ence in selecting novel stimuli after their initial introduc-
tion (rho = 0.41, P = 0.025) and a trend towards lower
persistence in selecting familiar options (rho = 0.36,
P = 0.055). This persistence in selecting novel options in
the drug-free state additionally predicted greater perform-
ance enhancement for ADHD participants when ON
stimulant medication (rho = 0.46, P = 0.011). No signifi-
cant relationships were observed between novelty and
drug-related changes in performance in the control
group (P4 0.1).
As the initial additive value of novel stimuli also decays
as a product of learning rate, any increase in learning rate
will result in a steeper decay of this value. Consequently,
valuation biases of novel stimuli will reduce over fewer
trials allowing potentially more accurate discrimination of
high and low value novel options. To recap, we observed a
significant increase in learning rate in ADHD participants
compared to effects in controls following stimulant medi-
cation. To investigate whether this differential effect of
medication on learning rate across groups improved
choice behaviour towards novel stimuli we examined the
number of consecutive trials in which participants chose
novel options when they were actually the optimal choice
(i.e. when the novel option actually had the greatest likeli-
hood of a payoff of all available choices) or non-optimal
(i.e. when the novel option did not have the greatest like-
lihood of a payoff of all available choices).
Across groups, participants showed a greater tendency to
persist with optimal rather than non-optimal novel options
[F(1,58) = 10.04, P = 0.002]. Neither medication nor group
status showed main effects on this. However, medication
did differentially affect how long the two groups selected
optimal versus non-optimal novel options
[Drug  Optimality  Group: F(1,58) = 4.80, P = 0.032]
(Fig. 2). Breaking this interaction down, in ADHD medica-
tion selectively enhanced persistence towards optimal com-
pared to non-optimal novel options (Optimal: Drug:
4.47  0.27; Placebo: 3.87  0.19; Non-optimal: Drug:
3.20  0.28; Placebo: 3.82  0.31) [Drug  Optimality:
F(1,28) = 7.60, P = 0.010]. However, this pattern of effects
was not observed in controls [Optimal: Drug: 4.12  0.13;
Placebo: 4.24  0.11; Non-optimal: Drug: 3.77  0.29;
Placebo: 3.64  0.25; Drug  Optimality F(1,28) = 0.25,
P = 0.624]. Across groups, participants also showed the ex-
pected tendency to persist with optimal rather than non-
optimal familiar options [F(1,58) = 37.80, P5 0.001].
However, medication did not differentially affect how
long the two groups selected optimal versus non-optimal
familiar options [Drug  Optimality  Group: F(1,58) =
0.49, P = 0.485]. This indicates that stimulant medication
selectively enhanced ADHD participants’ accuracy in dis-
criminating optimal from non-optimal novel but not famil-
iar options. This may reflect a steeper decay in the additive
value of novelty induced by stimulant medication in the
context of ADHD, which served to optimize decisions dir-
ected toward non-familiar (i.e. novel) stimuli.
Effects of treatment duration on
responses to novelty
Despite having a mean novelty bonus more than double
that of controls, ADHD patients showed marked interindi-
vidual differences that overshadowed the statistical signifi-
cance of group effects [F(1,58) = 1.59, P = 0.213]. Previous
studies show long-term alterations in striatal dopamine
availability following sustained methylphenidate use
(Wang et al., 2013). We therefore investigated whether,
individual differences in novelty bonus within the ADHD
group related to duration of treatment. Strikingly, this ana-
lysis demonstrated a significant negative correlation be-
tween treatment duration and baseline (unmedicated)
novelty bonus (rho = 0.44, P = 0.018), i.e. patients treated
the longest showed the lowest novelty bonuses.
Figure 2 Effects of stimulant medication on optimal
versus non-optimal novel choices. The mean number of times a
novel option was continuously selected after introduction, sepa-
rated according to whether it was the optimal choice (the highest
value option of the three on screen) or non-optimal choice (not the
highest value option of the three on screen).
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Relationship between reward- or
novelty-related behaviour and clinical
phenotype
Canonical correlation analysis was used to examine how
reward and novelty related behavioural features [novelty
bonus, learning rate, task performance (£won), and %
novel options selected on first appearance, all on and off
of medication] (set 1) related to clinical phenotype (inatten-
tion and hyperactivity/impulsivity domains of ADHD) (set
2). Briefly, this analysis derived latent canonical variates
from linear combinations of each of the two sets of vari-
ables, to maximize their covariance. Results demonstrated a
significant model [Wilk’s Lambda test: F(16,40) = 2.74,
P = 0.005] with a significant first (P = 0.005) but not
second (P = 0.126) pair of canonical variates. The first nov-
elty/reward derived canonical variate explained 63% of
variance in the ADHD clinical phenotype canonical variate
and 41% of overall ADHD phenotype (i.e. including items
not captured in the ADHD canonical variate). The ADHD
canonical variate was highly loaded by inattention scores
(r = 0.99) and moderately loaded by hyperactivity/impulsiv-
ity scores (r = 0.54). The novelty/reward canonical variate
was moderately loaded by OFF (r = 0.37) and ON medi-
cation learning rate (r = 0.36), ON medication amount won
(£) (r = 0.53) and % novel items picked on first appearance
(r = 0.65) and near-moderately loaded by OFF medication
novelty bonus (r = 0.29) (all other variable contributions
r5 |0.3|). Overall, these data provide evidence that nov-
elty/reward-related behavioural features explain up to
41% of the variance in clinical ADHD phenotype.
Striatal and substantia nigra reward
and novelty signals
Consistent with earlier reports (McClure et al., 2003;
O’Doherty et al., 2003; Pessiglione et al., 2006) computa-
tionally determined reward prediction error (base) showed
a tight correlation (FWE: P5 0.05) with bilateral ventral
striatum and orbitofrontal cortex activity (and several other
frontal and parietal regions) across groups (Fig. 3 and
Supplementary Table 1). In addition, we observed a signifi-
cant Group  Drug interaction for base within the left ven-
tral striatum [cluster SVC PFWE = 0.042; k = 15; Z = 3.51,
coordinates = (22 4 8)], where the ADHD group ex-
hibited a significant reduction in neural signals encoding
reward prediction error while on stimulant medication
compared to placebo. The opposite pattern was observed
in controls (Fig. 4A and B).
Across conditions, we did not observe a corresponding
correlation with novelty bonus signalling at the stringent
thresholds used here. However, complementing our find-
ings for reward prediction error, we observed a significant
Group  Drug interaction in the substantia nigra/ventral
tegmental area [whole brain cluster PFWE = 0.027,
k = 107, Z = 3.67, coordinates = (12 8 14)] indicating
a significant reduction of novelty-related signalling in
ADHD participants ON stimulant medication compared
to placebo, and a converse pattern observed in controls
(Fig. 4C and D). Corresponding to the reduction in behav-
ioural novelty bonus observed in patients who had been
ON medication for longer, activity within this cluster nega-
tively correlated with time ON medication [small volume
correction (SVC) FWE: P = 0.003].
Finally, we sought to investigate whether drug-related
reductions in baseline ventral striatal reward prediction
error signalling or substantia nigra/ventral tegmental area
novelty processing best explained the drug-induced en-
hancement of performance in ADHD. Consistant with
our behavioural findings, drug-induced reductions in sub-
stantia nigra/ventral tegmental area novelty-bonus signal-
ling (rho = 0.41, P = 0.025), but not ventral striatal
reward prediction error signalling (rho = 0.02, P = 0.930)
were related to improved task performance.
Discussion
Our results provide evidence of impaired reward and nov-
elty processing in ADHD and demonstrate attenuation of
these deficits by stimulant medication compared to effects
in controls. Furthermore, they identify a potential neuro-
computational mechanism underpinning these abnormal-
ities. Specifically, OFF medication ADHD participants
displayed a greater tendency to choose novel (but not fa-
miliar) stimuli on their first presentation. This tendency was
captured computationally as a higher (though statistically
non-significant) novelty bonus and a significantly lower rate
of value updating in response to reward (lower learning
rate). This heightened salience of novelty, coupled with a
Figure 3 Reward prediction error (base). Brain regions sig-
nificantly correlating with reward prediction error (base) across all
participants and conditions. Peak activations in right and left ventral
striatum are highlighted in red.
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slower decay in its rewarding properties, served to bias
ADHD patients to repeatedly select novel options even
when they were non-optimal. Interestingly, stimulant medi-
cation selectively remediated many of these abnormalities in
ADHD compared to effects in controls. For example, com-
pared to effects in controls, stimulant medication improved
ADHD participants’ overall task performance, reduced
their reward-learning rates and enhanced their ability to
differentiate optimal from non-optimal novel choices.
Aberrant persistence with selecting novel stimuli in the
drug-free state additionally predicted ADHD participants’
response to treatment. These findings were complimented
by our brain imaging data that showed that stimulant
medication resulted in a significant reduction in substantia
nigra/ventral tegmental area novelty-bonus signalling in
ADHD participants, which significantly correlated with
improved task performance. Finally, preliminary cross-sec-
tional evidence suggested an association between long-term
stimulant treatment and a reduction in the rewarding value
of novelty. Together, these results highlight a central role
for aberrant novelty processing in reward-related decision-
making abnormalities observed in ADHD. Moreover,
reward and novelty abnormalities appear to play an im-
portant role in the clinical phenotype of ADHD, with our
canonical correlation analysis revealing up to 41% of the
variance in clinical features of ADHD being explained by
differences in reward and novelty processing.
Previous modelling with simulated data has predicted
that hypo-dopaminergic abnormalities will reduce learning
rates and in turn account for key components of impulsive
reward dysfunction in ADHD (Williams and Dayan, 2005).
By showing that patients with ADHD exhibit reduced
reward-related learning rates OFF medication, we provide
the first empirical evidence to support this. In addition, our
data show a perturbation in the acquisition of reward-
related behaviours in ADHD, supporting models that pre-
dict slower learning following positive reinforcement
(Luman et al., 2010). This reduction in reward-learning
rate may also underlie observations of reduced adaptability
to changing reward schedules (Kollins et al., 1997) and
increased temporal discounting (Williams and Dayan,
2005) and help explain why reward-related learning deficits
Figure 4 Group by drug interaction for reward prediction error and novelty signals. (A) Brain regions demonstrating a significant
Group  Drug interaction for reward prediction error (base). Peak activation in the right ventral striatum highlighted in red. (B) Contrast
estimate for right ventral striatum cluster. (C) Brain regions demonstrating a significant Group  Drug interaction for novelty signal
(Qbase + base). Peak activation in the left substantia nigra highlighted in red. (D) Contrast estimate for left substantia nigra cluster.
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appear more pronounced when rewards are probabilistic or
intermittent rather than continuous (Aase and Sagvolden,
2006). Our results also suggest a tendency for stimulant
medication to improve both learning rates and reward-
learning task performance in ADHD participants compared
to controls. However, it should be cautioned that though
these differential effects were seen within groups in the raw
behavioural data (e.g. persistence in selecting optimal
versus non-optimal novel stimuli), effects on computational
parameters (e.g. learning rate) only survived statistical
thresholding in between group comparisons. Though sup-
portive of differential effects of stimulant medications in
ADHD patients and controls this will need to be confirmed
in future large scale clinical studies.
At first glance, the increased novelty and reward predic-
tion error signals we observed in ADHD may appear at
odds with the hypo-dopaminergic profile believed to be
central to this disorder. However, this divergence is pre-
dicted by a number of accounts of ADHD, which suggest
that despite a reduction in tonic dopamine, phasic dopa-
mine release is likely increased (Grace, 2001; Seeman and
Madras, 2002; Cherkasova et al., 2014; Badgaiyan et al.,
2015). While we cannot directly address this using our
functional MRI data, we do show heightened error and
novelty signals that are believed to be tightly linked to
phasic dopamine (Schultz, 2007). One possible mechanism
underpinning this heightened phasic novelty profile is lower
mesolimbic D2/D3 receptor density in ADHD (Volkow
et al., 2009, 2011). Functionally, a reduction in D2/D3
receptors would lead to disinhibited phasic dopamine re-
lease (Volkow et al., 2009, 2011), potentially explaining
the increased sensitivity to stimulus novelty and persistence
in selecting non-optimal novel options we observe.
Evidence to support this comes from molecular imaging
studies of trait novelty-seeking in the healthy population,
where lower D2/D3 (auto)receptor binding in substantia
nigra/ventral tegmental area is linked to higher novelty-
seeking traits (Zald et al., 2008). The reduction of substan-
tia nigra/ventral tegmental area novelty-bonus signalling
that we observe in ADHD participants after stimulant
medication may equally reflect increased inhibition of
these signals by D2/D3 activity, as methylphenidate exerts
at least some of its therapeutic effects via increased dopa-
mine binding to D2 receptors (Volkow et al., 2012).
Indeed, stimulant-induced enhancement of tonic dopamine
is predicted to preferentially activate D2/D3 receptors that
inhibit phasic dopamine (Dreyer et al., 2010).
In contrast to the beneficial effects we observe in ADHD
(reduced persistence in selecting non-optimal versus optimal
novel stimuli), methylphenidate did not significantly affect
behavioural responses to novelty in controls. Interestingly,
previous work has shown that in other, broader cognitive
domains, methylphenidate has similar effects in both
ADHD patients and controls (Agay et al., 2010). Thus,
while stimulant medication appears to have equal impact
on higher order cognitive functions in ADHD and controls
(Agay et al., 2010), it appears to engender different effects
on processes related to reinforcement-learning to reward
and novelty. Reinforcement-learning abnormalities may
therefore reflect a disorder-specific therapeutic target for
stimulant medication in ADHD. The fundamental origin
of these differential effects remains unclear, though likely
reflect baseline properties of the mesolimbic reward system.
Indeed, while enhanced tonic dopamine and D2 activity
may have a corrective role in ADHD and other hypo-dopa-
minergic disorders such as Parkinson’s disease (Rutledge
et al., 2009), increased D2 activity induced by methylphen-
idate in healthy controls (Volkow et al., 2001) may explain
their relatively poorer performance on drug compared to
effects in ADHD. Correspondingly, selective D2 agonists
appear to impair reward-learning in healthy subjects
(Pizzagalli et al., 2008).
A further, preliminary finding from our study was an
association between long-term stimulant treatment and a
relative attenuation of both novelty valuation and substan-
tia nigra/ventral tegmental area responsiveness to novelty.
The molecular mechanisms underpinning this potentially
sustained improvement in novelty valuation are unclear.
However, our findings may link observations that markers
of ventral striatal D2/D3 reactivity predict long-term symp-
tomatic improvements in attention (Volkow et al., 2012),
and prior associations between substantia nigra/ventral teg-
mental area D2/D3 receptor density and novelty-seeking
behaviour (Zald et al., 2008). Reductions in dopamine
transporter (DAT) density after long-term methylphenidate
treatment are largely interpreted as effects of tolerance
(Wang et al., 2013), yet a set of other neurobiological
changes ascribed to methylphenidate use may also underpin
potential long-term therapeutic benefits. These include
increased neuroplasticity (Dommett et al., 2008), dendritic
spine formation (Kim et al., 2009) and heightened expres-
sion of growth factors (Amiri et al., 2013; Roeding et al.,
2014; Simchon-Tenenbaum et al., 2015) within limbic cir-
cuitry supporting novelty processing, which may addition-
ally contribute to long-term therapeutic effects, independent
of current stimulant medication status.
In addition to effects on DAT, stimulant medications also
block norepinephrine reuptake. Further, atomoxetine, a se-
lective norepinephrine reuptake inhibitor with minimal
action on DAT also shows clinical efficacy in ADHD (Del
Campo et al., 2011). Therefore, the differences in reward
and novelty processing we observed may, at least in part,
be mediated through noradrenergic mechanisms. This inter-
pretation may also inform several discrepancies between
our findings and other work. For instance, recent findings
in monkeys using a highly selective DAT inhibitor have
shown that though this increased the valuation of novel
stimuli (broadly in line with our findings in healthy indi-
viduals), it elicited no change in learning rate (Costa et al.,
2014). This suggests that our observed effects on learning
rate may have been mediated through noradrenergic mech-
anisms. This interpretation may similarly apply to our as-
sociation between long-term medication use and a lower
novelty bonus as individuals with Parkinson’s disease and
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compulsive behaviours arising from dopamine agonist ex-
posure are reported to show elevated novelty preference
(Djamshidian et al., 2011). Alternately, this discrepancy
may reflect different dopaminergic mechanisms of action
(e.g. agonists, versus dopamine reuptake inhibitors) or dif-
ferent baseline properties of the dopamine system in these
populations. With regards the latter point, it is noteworthy
that short-term effects of these medications appeared to
differ according to the population studied (in this case
ADHD versus healthy controls). Further, not all individuals
with Parkinson’s disease given dopaminergic medications
develop impulsive and compulsive behaviours. While our
current work cannot ultimately disentangle differential
dopaminergic and noradrenergic effects, future work may
seek to examine the effects of selective noradrenergic re-
uptake inhibitors such as atomoxetine on novelty signalling
in ADHD and control participants.
This work must be interpreted in the light of several limi-
tations. First, we report results from a sample with prior
exposure to stimulant medication. Though this was done to
ensure a sample in which these medications were clinically
efficacious, differential effects of medication observed
across groups may have been influenced by differences in
prior exposure. Second, our task was designed to mirror
that of Wittmann et al. (2008) in healthy controls. A weak-
ness of this task design is that it does not allow complete
temporal separation of Q and  [correlation of Q and 
across trials suggested 18.4% of shared variance (R2)].
Though this indicates that our prediction error results are
unlikely to be substantially contaminated by differences in
value signals, it did mandate that like Wittmann, our pri-
mary outcome variable (novelty bonus) was a combination
of Qadd and add. Finally, our data were acquired at a field
strength of 1.5 T. Though signal-to-noise will have been
enhanced by our use of a 32-channel head coil, a higher
performing system may have been sensitive to smaller ef-
fects in regions we have not reported.
Further work is required to consolidate the broader clin-
ical implications of the aberrant responses to novelty
observed here. For example, in addition to apparent roles
in inattention and poor decision-making, heightened nov-
elty valuation could well contribute to the high prevalence
of substance use disorders observed in ADHD. Conversely,
the apparent reduction in novelty valuation we observe
with prolonged treatment could underlie the reported re-
duction in substance abuse risks associated with long-term
medication use (Wilens et al., 2003; Mannuzza et al.,
2008). Longitudinal data are clearly required to investigate
this hypothesis. To conclude, our findings suggest that nov-
elty valuation has an important role in defining the ADHD
phenotype and likely treatment response. Indeed, effects of
methylphenidate on novelty processing revealed a remark-
ably disorder-specific effect not observed for other broader
neuropsychological domains (Agay et al., 2010). Thus,
while some of the beneficial effects conferred by stimulant
medication appear compensatory rather than corrective,
actions on reinforcement-learning, and novelty processing
in particular, appear to represent specific pathological
targets.
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